Publications

5677 Results

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

Authors
P Torka;A Bock;E Nazarenko;Y Xu;J Vaughn;S Thiruvengadam;A Major;K Sekaran;D Reef;C Lee;G Smilnak;E Luttwak;V Patel;H Shah;A Ip;G Baek;R Mynam;D Sano;D Gerber;A Falade;M Palmeri;R Mrad;M Iqbal;J Sharp;T Voorbees;P Geethakumari;J Rbodes;U Durani;H Cherng;Y Karimi;P Pophali;M Di;T Feldman;J Svoboda;K Shanmugasundaram;A Niu;N Grover;R Karmali;A Herrera;C Diefenbach;N Epperla
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL) #3622 poster
Year
2025
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Clinical prognostication in the SWOG 1826 randomized clinical trial of nivolumab-AVD versus brentuximab-AVD: Performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI)

Authors
C Casulo;H Li;A Herrera;S Castellino;S Rutherford;K Davison;A Punnett;B Kahl;J Leonard;S Smith;J Song;K Kelly;J Friedberg;M LeBlanc;S Parsons;A Rodday;A Evens
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL), #154 oral
Year
2025
Research Committee(s)
Lymphoma

Identifying fusions in AML/MDS: An experience from first 400 patients enrolled into myelomatch

Authors
S Jiwani;M Fang;C Yeung;X QU;X Chen;B Wood;A Zak
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL) #3622, #340, oral
Year
2025
Research Committee(s)
Leukemia

Bone biomarkers and subsequent survival in men with hormone sensitive prostate cancer: results from the SWOG S1216 phase III trial of androgen deprivation therapy with or without orteronel

Authors
P Lara;E Mayerson;E Gertz;C Tangen;A Goldkorn;M Van Loan;M Hussain;S Gupta;J Zhang;M Parikh;P Twardowski;D Quinn;N Vogelzang;I Thompson;N Agarwal
Journal / Conference
European Urology Feb;85(2):171-176
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID37085425
PMC
PMC10662935
Study Number(s)
S1216

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

Authors
C Gallois;Q Shi;J Meyers;T Iveson;S Alberts;A De Gramont;A Sobrero;D Haller;E Oki;A Shields;R Goldberg;R Kerr;S Lonardi;G Yothers;C Kelly;I Boukovinas;R Labianca;F Sinicrope;I Souglakos;T Yoshino;J Meyerhardt;T Andre;D Papamichael;J Taieb
Journal / Conference
Journal of Clinical Oncology
Year
2024
Research Committee(s)
Gastrointestinal
PMID
PMID38547438
Study Number(s)
CTSU/C80702

A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

Authors
G Garcia-Manero;N Podoltsev;M Othus;J Pagel;J Radich;M Fang;D Rizzieri;G Marcucci;SA Strickland;MR Litzow;M Savoie;B Medeiros;M Sekeres;TL Lin;G Uy;BL Powell;JE Kolitz;RA Larson;RM Stone;D Claxton;J Essell;S Luger;S Mohan;A Moseley;F Appelbaum;HP Erba
Journal / Conference
Leukemia Jan;38(1):58-66
Year
2024
Research Committee(s)
Leukemia
PMID
PMID37935977
Study Number(s)
S1203

Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

Authors
S Lerner;D McConkey;C Tangen;JJ Meeks;T Flaig;X Hua;S Daneshmand;A Alva;MS Lucia;D Theodorescu;A Goldkorn;M Milowsky;W Choi;R Bangs;D Gustafson;M Plets;IM Thompson
Journal / Conference
Clinical Cancer Research Jan 17;30(2):444-449
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID37966367
PMC
PMC10824507
Study Number(s)
S1314

A phase II basket trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia

Authors
S Patel;M Othus;Y Chae;M Dennis;S Gordon;D Mutch;W Samlowski;W Robinson;E Sharon;C Ryan;G Lopez;M Plets;C Blanke;R Kurzrock
Journal / Conference
Clinical Cancer Research Jan 5;30(1):33-38
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID37882676
PMC
PMC10842092
Study Number(s)
S1609

Predicting clinical outcomes in the S1314-COXEN Trial using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression

Authors
B Faltas;Z Bai;M Osman;M Brendel;C Tangen;T Flaig;M Plets;MS Lucia;D Theodorescu;D Gustafson;S Daneshmand;J Meeks;W Choi;C Dinney;O Elemento;S Lerner;D McConkey;F Wang
Journal / Conference
ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), oral
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S1314

PAPMET2 A Phase II Randomized Trial of Cabozantinib with or without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma (PRCC): SWOG S2200)

Authors
B Maughan;M Plets;Y Ged;C Tangen;U Vaishampayan;S Lerner;S Lerner;I Thompson
Journal / Conference
ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), TIPS, poster
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S2200